Your Gateway to Power, Energy, Datacenters, Bitcoin and AI
Dive into the latest industry updates, our exclusive Paperboy Newsletter, and curated insights designed to keep you informed. Stay ahead with minimal time spent.
Discover What Matters Most to You

AI
Lorem Ipsum is simply dummy text of the printing and typesetting industry.

Bitcoin:
Lorem Ipsum is simply dummy text of the printing and typesetting industry.

Datacenter:
Lorem Ipsum is simply dummy text of the printing and typesetting industry.

Energy:
Lorem Ipsum is simply dummy text of the printing and typesetting industry.
Discover What Matter Most to You
Featured Articles

What’s next for IVF
EXECUTIVE SUMMARY Forty-eight years ago this July, Louise Joy Brown became the world’s first person born with the help of in vitro fertilization. Millions more IVF babies have entered the world since then. And that’s partly thanks to advances in technology that have made IVF safer and more effective. But it’s still not perfect. The process can be slow, painful, and expensive—and that’s for the lucky people who are able to access it in the first place. And by at least one measure, IVF success rates have been declining in recent years. Reproduction is complex, and there’s a lot that embryologists and gynecologists still don’t know and can’t control. They don’t know why many healthy-looking embryos don’t “stick” in the uterus, for example. They don’t always have an explanation for why their patients can’t get pregnant. And they can’t always account for vast differences in IVF success rates between individuals and between fertility clinics. Scientists are working on all those questions and more. They’re wrestling with complex ethical questions about how new genetic tools will be used to analyze or even alter embryos. Meanwhile, technologies designed to standardize treatment, eliminate human error, boost success rates, and make IVF more accessible are already beginning to usher in a new era for assisted reproduction—one aided by AI and robots.
1. Helping embryos stick Some of those technologies are being developed at the Carlos Simon Foundation in Valencia, Spain. When I visited in March, researchers gave me a tour of the labs and showed me a device that had been used to keep a human uterus alive outside the body for the first time. While some members of the team dream of building artificial uteruses that might one day be able to carry a fetus to term, they first want to use such devices to learn more about implantation—the moment at which a fertilized egg makes contact with the lining of the uterus, burrows inside, and essentially “hatches,” triggering the start of a pregnancy.
Despite decades of advances in IVF, that process is still poorly understood. Even healthy-looking embryos stick no more than 40% to 60% of the time. In IVF techniques used today, clinics can create early-stage embryos and wait until the uterus is deemed most receptive, but once they insert the embryo into the uterus, it’s on its own. Xavier Santamaria, senior clinical scientist at the Carlos Simon Foundation, and his colleagues are trialing a different approach. They’ve developed a device that, at the press of a button, injects the embryo into the uterine lining. JESS HAMZELOU / MITTR In a demonstration I watched with a prototype, Santamaria picked up his speculum and turned to face the vaginal opening of his “patient,” which in this case was just a model of the real thing—a plastic bottom with labia, a vagina, a uterus, and ovaries, two short stumps representing what would normally be a pair of legs held in stirrups. He hunched over and peered inside. “Embryo,” he called. His colleague Maria Pardo, an embryologist, passed him a thin needle containing a mouse embryo she had recently collected from a petri dish. Santamaria’s device allows for the embryo-containing needle to be connected to a delivery tube. This tube also has a camera, a light, and a sensor that lets the doctor know when the needle reaches the uterine lining. Once it has been fed into the uterus, the gynecologist can see the inside of the organ and direct the tube to the lining. JESS HAMZELOU / MITTR “When everything is ready, you just press the button,” Santamaria said as he activated it using a foot pedal, allowing the embryo to be injected. “There it goes.” The team has just started a trial of the device; so far, fewer than 10 women have undergone the procedure, and none of those have become pregnant. But foundation director Carlos Simon is hopeful, noting that the inventors of IVF had to perform over 160 cycles before Louise Brown was born (between 1969 and 1978, that team performed 457 cycles in 250 people, resulting in only two live births). “The trial is ongoing,” he says. 2. Picking the “best” eggs, sperm, and embryos One long-running challenge of IVF has been selection. Say you manage to collect 10 eggs from one partner and a decent-looking semen sample from the other. How do you choose which cells to use? The same question comes up once the resulting embryos have been cultured in a dish for a few days: Which should you transfer to the uterus?
Traditionally, these judgments have been made by eye. Embryologists literally pick the ones that look the best in terms of their shape or, in the case of sperm, how they move. But scientists have been working on alternatives. And over the last decade or so, many have turned to genetic testing to hint at which embryos have the best chances of creating a healthy baby. The most commonly used test is called PGT-A, which stands for preimplantation genetic testing for aneuploidy. Aneuploidy essentially means having an “incorrect” number of chromosomes, and it is thought that embryos with such characteristics are more likely to be lost through miscarriage or potentially develop into babies with genetic conditions. Once embryologists have created embryos in the lab, they can pinch off a few cells and test them for aneuploidies. The tests are especially beneficial for women over the age of 38, says Alan Penzias, a reproductive endocrinologist at Boston IVF. “You start to see an improvement: more babies and fewer miscarriages,” he says. The tests can shorten the time to pregnancy. This type of genetic testing is possible thanks to multiple advances in technology—not just in genomics, but also in the ability to keep embryos alive in a dish for five to six days and the technique of freezing embryos while the cells undergo testing and thawing them once the results are in. And it has become hugely popular—some clinics do PGT-A tests on all their embryos. But PGT-A won’t give you a perfect readout of a future baby’s genetics, says Sonia Gayete-Lafuente, a reproductive endocrinologist at the Center for Human Reproduction in New York City. And some of the abnormalities might be able to self-correct with time. Gayete-Lafuente and her colleagues have transferred some of those “abnormal” embryos into patients’ uteruses and seen them develop into perfectly healthy children, she says. Other forms of PGT are even more controversial. PGT-P tests are designed to predict an embryo’s chances of developing complex traits that rely on multiple genes, including medical disorders but also physical characteristics like height or cognitive factors like IQ. These tests are new, and they are illegal in some countries, including the UK. But they are gaining ground in the US. Nucleus Genomics—a company that invites customers to “have [their] best baby”—promises to predict traits running the gamut from eye color and intelligence to left-handedness and risk of Alzheimer’s. When I asked IVF practitioners how they might respond if a patient asked for this service, most dodged the question and told me there’s not enough evidence that any of these tests actually work. They also cautioned that selecting for one trait might inadvertently introduce new risks. None seemed especially keen on the idea of using genetic testing for anything other than preventing serious disease. 3. Speeding things up with AI Some seemed more excited about the potential for AI. After all, AI tools are generally good at recognizing patterns. Many researchers have attempted to train tools to spot healthy sperm, eggs, and embryos.
And they’ve had some success. A team at Columbia University Medical Center in New York has developed a device that uses AI to examine semen samples from men who have only tiny numbers of healthy sperm. An embryologist might struggle to find a single healthy sperm in such a sample. But the Sperm Tracking and Recovery (STAR) system can analyze over a million microscope images in an hour. It has already been used to create healthy embryos. The team behind the work announced the first pregnancy resulting from the treatment in November last year. Other teams are using AI tools to advance IVF in more dramatic ways. Around a decade ago, a reproductive endocrinologist named Alejandro Chavez-Badiola began developing an AI tool trained to rank embryos, another to rank eggs, and another to select sperm. He recalls being struck by a realization that these tools were “the brains that have the potential to drive robots in the future,” he says.
4. Using robots to standardize IVF In the early 2020s, Chavez-Badiola and his colleagues decided to combine technologies and develop an automated system for IVF. In theory, a robotic system loaded up with AI tools could undertake most of the steps required in the IVF process: selecting the eggs and sperm, fertilizing eggs to create embryos, culturing those embryos in a dish, and selecting the “best” one for transfer. Such a system could “do everything in a standard way” without ever getting tired, he says. Chavez-Badiola, who is now founder and chief medical officer at Conceivable, started building prototypes by motorizing regular IVF equipment and connecting it to computers. He and his colleagues started testing their system with animal cells before eventually moving on to human ones. “We were able to prove that integrating robots to automate different steps in IVF is doable,” he says. The device is now being used to prepare sperm and eggs and create embryos. At least 19 children have been born following the automated IVF. It is early days, but Chavez-Badiola is hoping that future iterations of the machine could each process thousands of IVF cycles in a year, potentially making the procedure more affordable and accessible. Many in the field are excited about the potential for automated devices like Conceivable’s. “This is all time saved for the embryologists,” says Laura Rienzi, a clinical embryologist and scientific director of the IVIRMA network of fertility centers in Italy. She also hopes it will help standardize IVF treatments. “Automation [will allow for] every patient to be treated in the same way in every single lab in the world,” she says. 5. Controversial edits are on the table There’s a catch, however: All these technologies rely on the availability of at least some healthy sperm, eggs, and embryos at the outset. Embryologists and IVF patients have to work with what they’ve got. And sometimes, what they’ve got won’t result in a healthy baby. That’s why some scientists are proposing a controversial idea: using gene-editing technologies like CRISPR to tinker with the genome of an IVF embryo before it is implanted. The biophysicist He Jiankui infamously took this approach to create embryos that resulted in the births of three children in the late 2010s. He was widely condemned by the scientific community and ultimately spent three years in a Chinese prison.
His former romantic partner Cathy Tie, who now leads startup Origin Genomics, is pursuing the technology as a potential way to prevent serious disease in children. At a recent event held at the Hastings Center for Bioethics, Tie made the case for using embryo editing to prevent diseases like cystic fibrosis, Huntington’s, and sickle-cell. It won’t be straightforward from a technical, legal, or ethical perspective. Diseases that are known to be caused by single-gene mutations are good first candidates, but as the Center for Human Reproduction’s Gayete-Lafuente points out, most diseases are much more complicated than that. “I wish we could understand the genetic basis of every disease to be able to prevent it,” she says. So far, we can’t. Besides, most diseases can be influenced by our diets, behaviors, and environments as well as our genes. As things stand, no one knows if editing a human embryo to eliminate the risk of one disease might increase a future child’s risk of some other disorder. And some scientists worry that such edits might be a slippery slope to genetic enhancement or eugenics. Rienzi hopes that the technology might be developed in a safe way with regulatory oversight, and only for a specific list of diseases. “It has to be within a legal context,” she says. “But to me, it’s a dream.” In the meantime, the field looks set to keep transforming with the development of new technologies that are already creating healthy babies. Watch this space.

Supply constraints, optical advances dominate Arista’s Q1
“While the industry has been talking a lot about co-packaged optics, these are still science experiments, and they’re very proprietary with individual vendors doing their own thing. We’ll embrace open CPO a few years from now, but we think XPO has a 10-year run, especially at 1.6T and 3.2T where you need liquid cooling and you need that kind of capacity. So, all the scale-up racks we’re talking about wouldn’t be possible without XPO or CPC or any one of those technologies,” Ullal said. “Just as the last decade was greatly influenced by OSFP, the next decade will be greatly influenced by XPO,” Ullal said. “And remember, 99% of the optical market today that we connect to is all pluggable optics. So this is a very crucial invention and innovation, not just for Arista, but the industry at large.” Enterprise AI: Calm before the storm? When it comes to AI for enterprise network customers, Arista’s Ullal says it’s just getting started. The company is seeing a shift from AI training toward more AI inference, “which means you don’t always need the GPU,” Ullal said. “You’re going to have high-end CPUs, and you’re going to have a smaller set of parameters and tokens to manage, and you’re going to have specific agentic AI use cases and applications. We’re seeing very, very early trials and stages. Nothing super big yet.” Some customers are deploying clusters that are “more inference-based, more agentic AI, edge, inference-based as well,” Ullas said. “I think we’ll see more of that. This is the calm before the storm, if you will. As AI gets more distributed, I think it doesn’t need GPUs alone. It’s going to need more high-performance compute… I think it’s gonna take a couple of years to fully happen.”

Lumen advances cloud networking vision with $475M Alkira buy
Lumen puts its total addressable market at approximately $70 billion once Alkira’s international and cloud-to-cloud coverage is included. “Alkira is a bull’s eye in terms of strategic alignment and value creation,” Johnson said. “For Lumen, we expect it to dramatically accelerate our road map execution from years to months.” How the architecture works Alkira operates as a cloud-native, carrier-agnostic control plane. Rather than relying on physical hardware at each interconnection point, it uses a virtual port model that lets enterprises design, deploy and manage network connectivity across clouds, data centers and on-premises environments through a single interface. Alkira is distinct from Lumen’s existing Project Berkeley, which introduces fabric ports for building-to-cloud on-ramp connectivity. “Fabric ports is about enabling building on-prem to be able to connect to the cloud and to be able to grow those services in a cloud economic way,” Johnson said. “The Alkira platform really focuses on the East-West interconnect. So that’s data center-to-data center, cloud-to-cloud, so they operate with more of a virtual port kind of a model, and it’s better together.” Lumen’s Multi-Cloud Gateway bridges the two domains, enabling customers to connect any cloud and any data center over Lumen’s private network. After close, Multi-Cloud Gateway and Alkira together are intended to give customers a single control plane for routing, policy and security across both north-south and east-west connectivity.

NNPC advances rehab, expansion plans for idled refineries
Nigeria National Petroleum Corp. Ltd. (NNPC) has entered a memorandum of understanding (MOU) with China-based Sanjiang Chemical Co. Ltd. and Xinganchen (Fuzhou) Industrial Park Operation and Management Co. Ltd. for collaboration via a potential technical equity partnership to support ongoing rehabilitation and expansion plans at two of its currently idled in-country refining complexes. Announced in early May, the MOU’s proposed framework covers unspecified remaining rehabilitation works at subsidiary Warri Refining & Petrochemical Co. Ltd.’s (WRPC) 125,000-b/sd refinery in Nigeria’s Delta State and Port Harcourt Refining Co. Ltd.’s (PHRC) 60,000-b/sd hydroskimming refinery at Alesa-Eleme near Port Harcourt in Rivers State, NNPC said. Alongside operating and maintenance activities to help the sites achieve best-in-class, sustainable performance, the MOU also outlines proposed expansions and upgrades at both refineries to enable production of cleaner, higher-valued products, according to the company. While NNPC did not clarify the nature of expansion and upgrading plans for either of the refining sections of the sites, the operator said the potential collaboration with Sanjiang Chemical and and Xinganchen (Fuzhou) Industrial Park also would weigh options for expanding the two complex’s petrochemical capabilities, as well as future development of co-located, gas-based industrial hubs at the two locations. NNPC said formal signing of the MOU follows more than 6 months of technical and management discussions with the two Chinese firms to develop a roadmap for restoring sustained, high-performance manufacturing operations at both sites. The MOU comes as part of NNPC’s broader mission to identify potential privately held technical equity partners to help support rehabilitation and expansion of its existing but nonoperational refining infrastructure, which ideally would include a willingness to evaluate opportunities for adding co-located petrochemical production and gas-based industries at the sites, the operator said. The agreement with Sanjiang Chemical and and Xinganchen (Fuzhou) Industrial Park follows NNPC’s announcement earlier

OTC speakers say Venezuela reopening hinges on stability, legal clarity
The conversation comes as the Trump administration continues easing sanctions and encouraging American operators to re-engage with Venezuela’s oil and gas sector. Signs are growing that major international energy companies are reassessing opportunities in the country. ExxonMobil and ConocoPhillips have recently dispatched technical teams to evaluate oilfield infrastructure and upstream prospects, while Gulf Coast refiners have already increased imports of Venezuelan heavy crude. Panelists said the central question facing US energy companies is no longer whether Venezuela will reopen, but whether the conditions, pace, and overall risk profile of that reopening are sufficient to support large-scale, long-term capital investment. Speakers noted that Venezuela’s appeal extends far beyond short-term political change. The country holds one of the world’s largest and most diverse hydrocarbon resource bases, including extra-heavy crude in the Orinoco Belt, conventional light and medium oil, and significant offshore natural gas resources. The opportunity lies not only in the size of the resource base, but also in the long-term development potential, the panelists said. However, years of underinvestment, deteriorating infrastructure, and labor losses mean rebuilding the sector will require significant technical expertise and sustained capital commitments. Oilfield service companies are expected to play an important role if activity accelerates, particularly in offshore gas, heavy oil upgrading, drilling services, and infrastructure rehabilitation. Recent reports indicate service providers have already begun reactivating rigs and equipment stored in Venezuela in anticipation of renewed activity. Speakers emphasized that investors are seeking stable policies and durable legal frameworks before committing capital at scale. Trust in Venezuela’s legal and regulatory system remains weak following years of expropriations and contract disputes. Companies must evaluate not only Venezuela’s domestic political outlook, but also the broader geopolitical dynamics involving the US and China, Borrego noted. China’s long-standing investments and influence in Venezuela’s energy sector were referenced as an important

HPE bolsters autonomous network operations for Mist, Aruba Central
Outside of the wireless realm, HPE has added the ability to autonomously fix VLAN configuration errors in the access layer to prevent blackholing of client traffic and detect/remediate unauthorized DHCP servers. The idea is to mitigate potential external security risks and prevent end user connectivity disruptions, according to a blog post penned by Selena Mosley, HPE Marvis product marketing manager. “A rogue DHCP server—often introduced unintentionally through a BYOD device—can misassign IP addresses and take down entire areas. Marvis detects the anomaly, traces it to the exact switch port, and can automatically contain it, reducing blast radius and restoring service quickly,” Mosley wrote. “Or consider missing VLANs, a common cause of connected but not working scenarios during day‑0 or day‑2 changes. Marvis correlates client telemetry, configuration state, and Marvis Minis validations to identify the mismatch and either remediate automatically or guide the operator with a single action. In each case, the outcome is the same: fewer escalations, faster resolution, and consistent application experience,” Mosley wrote.

What’s next for IVF
EXECUTIVE SUMMARY Forty-eight years ago this July, Louise Joy Brown became the world’s first person born with the help of in vitro fertilization. Millions more IVF babies have entered the world since then. And that’s partly thanks to advances in technology that have made IVF safer and more effective. But it’s still not perfect. The process can be slow, painful, and expensive—and that’s for the lucky people who are able to access it in the first place. And by at least one measure, IVF success rates have been declining in recent years. Reproduction is complex, and there’s a lot that embryologists and gynecologists still don’t know and can’t control. They don’t know why many healthy-looking embryos don’t “stick” in the uterus, for example. They don’t always have an explanation for why their patients can’t get pregnant. And they can’t always account for vast differences in IVF success rates between individuals and between fertility clinics. Scientists are working on all those questions and more. They’re wrestling with complex ethical questions about how new genetic tools will be used to analyze or even alter embryos. Meanwhile, technologies designed to standardize treatment, eliminate human error, boost success rates, and make IVF more accessible are already beginning to usher in a new era for assisted reproduction—one aided by AI and robots.
1. Helping embryos stick Some of those technologies are being developed at the Carlos Simon Foundation in Valencia, Spain. When I visited in March, researchers gave me a tour of the labs and showed me a device that had been used to keep a human uterus alive outside the body for the first time. While some members of the team dream of building artificial uteruses that might one day be able to carry a fetus to term, they first want to use such devices to learn more about implantation—the moment at which a fertilized egg makes contact with the lining of the uterus, burrows inside, and essentially “hatches,” triggering the start of a pregnancy.
Despite decades of advances in IVF, that process is still poorly understood. Even healthy-looking embryos stick no more than 40% to 60% of the time. In IVF techniques used today, clinics can create early-stage embryos and wait until the uterus is deemed most receptive, but once they insert the embryo into the uterus, it’s on its own. Xavier Santamaria, senior clinical scientist at the Carlos Simon Foundation, and his colleagues are trialing a different approach. They’ve developed a device that, at the press of a button, injects the embryo into the uterine lining. JESS HAMZELOU / MITTR In a demonstration I watched with a prototype, Santamaria picked up his speculum and turned to face the vaginal opening of his “patient,” which in this case was just a model of the real thing—a plastic bottom with labia, a vagina, a uterus, and ovaries, two short stumps representing what would normally be a pair of legs held in stirrups. He hunched over and peered inside. “Embryo,” he called. His colleague Maria Pardo, an embryologist, passed him a thin needle containing a mouse embryo she had recently collected from a petri dish. Santamaria’s device allows for the embryo-containing needle to be connected to a delivery tube. This tube also has a camera, a light, and a sensor that lets the doctor know when the needle reaches the uterine lining. Once it has been fed into the uterus, the gynecologist can see the inside of the organ and direct the tube to the lining. JESS HAMZELOU / MITTR “When everything is ready, you just press the button,” Santamaria said as he activated it using a foot pedal, allowing the embryo to be injected. “There it goes.” The team has just started a trial of the device; so far, fewer than 10 women have undergone the procedure, and none of those have become pregnant. But foundation director Carlos Simon is hopeful, noting that the inventors of IVF had to perform over 160 cycles before Louise Brown was born (between 1969 and 1978, that team performed 457 cycles in 250 people, resulting in only two live births). “The trial is ongoing,” he says. 2. Picking the “best” eggs, sperm, and embryos One long-running challenge of IVF has been selection. Say you manage to collect 10 eggs from one partner and a decent-looking semen sample from the other. How do you choose which cells to use? The same question comes up once the resulting embryos have been cultured in a dish for a few days: Which should you transfer to the uterus?
Traditionally, these judgments have been made by eye. Embryologists literally pick the ones that look the best in terms of their shape or, in the case of sperm, how they move. But scientists have been working on alternatives. And over the last decade or so, many have turned to genetic testing to hint at which embryos have the best chances of creating a healthy baby. The most commonly used test is called PGT-A, which stands for preimplantation genetic testing for aneuploidy. Aneuploidy essentially means having an “incorrect” number of chromosomes, and it is thought that embryos with such characteristics are more likely to be lost through miscarriage or potentially develop into babies with genetic conditions. Once embryologists have created embryos in the lab, they can pinch off a few cells and test them for aneuploidies. The tests are especially beneficial for women over the age of 38, says Alan Penzias, a reproductive endocrinologist at Boston IVF. “You start to see an improvement: more babies and fewer miscarriages,” he says. The tests can shorten the time to pregnancy. This type of genetic testing is possible thanks to multiple advances in technology—not just in genomics, but also in the ability to keep embryos alive in a dish for five to six days and the technique of freezing embryos while the cells undergo testing and thawing them once the results are in. And it has become hugely popular—some clinics do PGT-A tests on all their embryos. But PGT-A won’t give you a perfect readout of a future baby’s genetics, says Sonia Gayete-Lafuente, a reproductive endocrinologist at the Center for Human Reproduction in New York City. And some of the abnormalities might be able to self-correct with time. Gayete-Lafuente and her colleagues have transferred some of those “abnormal” embryos into patients’ uteruses and seen them develop into perfectly healthy children, she says. Other forms of PGT are even more controversial. PGT-P tests are designed to predict an embryo’s chances of developing complex traits that rely on multiple genes, including medical disorders but also physical characteristics like height or cognitive factors like IQ. These tests are new, and they are illegal in some countries, including the UK. But they are gaining ground in the US. Nucleus Genomics—a company that invites customers to “have [their] best baby”—promises to predict traits running the gamut from eye color and intelligence to left-handedness and risk of Alzheimer’s. When I asked IVF practitioners how they might respond if a patient asked for this service, most dodged the question and told me there’s not enough evidence that any of these tests actually work. They also cautioned that selecting for one trait might inadvertently introduce new risks. None seemed especially keen on the idea of using genetic testing for anything other than preventing serious disease. 3. Speeding things up with AI Some seemed more excited about the potential for AI. After all, AI tools are generally good at recognizing patterns. Many researchers have attempted to train tools to spot healthy sperm, eggs, and embryos.
And they’ve had some success. A team at Columbia University Medical Center in New York has developed a device that uses AI to examine semen samples from men who have only tiny numbers of healthy sperm. An embryologist might struggle to find a single healthy sperm in such a sample. But the Sperm Tracking and Recovery (STAR) system can analyze over a million microscope images in an hour. It has already been used to create healthy embryos. The team behind the work announced the first pregnancy resulting from the treatment in November last year. Other teams are using AI tools to advance IVF in more dramatic ways. Around a decade ago, a reproductive endocrinologist named Alejandro Chavez-Badiola began developing an AI tool trained to rank embryos, another to rank eggs, and another to select sperm. He recalls being struck by a realization that these tools were “the brains that have the potential to drive robots in the future,” he says.
4. Using robots to standardize IVF In the early 2020s, Chavez-Badiola and his colleagues decided to combine technologies and develop an automated system for IVF. In theory, a robotic system loaded up with AI tools could undertake most of the steps required in the IVF process: selecting the eggs and sperm, fertilizing eggs to create embryos, culturing those embryos in a dish, and selecting the “best” one for transfer. Such a system could “do everything in a standard way” without ever getting tired, he says. Chavez-Badiola, who is now founder and chief medical officer at Conceivable, started building prototypes by motorizing regular IVF equipment and connecting it to computers. He and his colleagues started testing their system with animal cells before eventually moving on to human ones. “We were able to prove that integrating robots to automate different steps in IVF is doable,” he says. The device is now being used to prepare sperm and eggs and create embryos. At least 19 children have been born following the automated IVF. It is early days, but Chavez-Badiola is hoping that future iterations of the machine could each process thousands of IVF cycles in a year, potentially making the procedure more affordable and accessible. Many in the field are excited about the potential for automated devices like Conceivable’s. “This is all time saved for the embryologists,” says Laura Rienzi, a clinical embryologist and scientific director of the IVIRMA network of fertility centers in Italy. She also hopes it will help standardize IVF treatments. “Automation [will allow for] every patient to be treated in the same way in every single lab in the world,” she says. 5. Controversial edits are on the table There’s a catch, however: All these technologies rely on the availability of at least some healthy sperm, eggs, and embryos at the outset. Embryologists and IVF patients have to work with what they’ve got. And sometimes, what they’ve got won’t result in a healthy baby. That’s why some scientists are proposing a controversial idea: using gene-editing technologies like CRISPR to tinker with the genome of an IVF embryo before it is implanted. The biophysicist He Jiankui infamously took this approach to create embryos that resulted in the births of three children in the late 2010s. He was widely condemned by the scientific community and ultimately spent three years in a Chinese prison.
His former romantic partner Cathy Tie, who now leads startup Origin Genomics, is pursuing the technology as a potential way to prevent serious disease in children. At a recent event held at the Hastings Center for Bioethics, Tie made the case for using embryo editing to prevent diseases like cystic fibrosis, Huntington’s, and sickle-cell. It won’t be straightforward from a technical, legal, or ethical perspective. Diseases that are known to be caused by single-gene mutations are good first candidates, but as the Center for Human Reproduction’s Gayete-Lafuente points out, most diseases are much more complicated than that. “I wish we could understand the genetic basis of every disease to be able to prevent it,” she says. So far, we can’t. Besides, most diseases can be influenced by our diets, behaviors, and environments as well as our genes. As things stand, no one knows if editing a human embryo to eliminate the risk of one disease might increase a future child’s risk of some other disorder. And some scientists worry that such edits might be a slippery slope to genetic enhancement or eugenics. Rienzi hopes that the technology might be developed in a safe way with regulatory oversight, and only for a specific list of diseases. “It has to be within a legal context,” she says. “But to me, it’s a dream.” In the meantime, the field looks set to keep transforming with the development of new technologies that are already creating healthy babies. Watch this space.

Supply constraints, optical advances dominate Arista’s Q1
“While the industry has been talking a lot about co-packaged optics, these are still science experiments, and they’re very proprietary with individual vendors doing their own thing. We’ll embrace open CPO a few years from now, but we think XPO has a 10-year run, especially at 1.6T and 3.2T where you need liquid cooling and you need that kind of capacity. So, all the scale-up racks we’re talking about wouldn’t be possible without XPO or CPC or any one of those technologies,” Ullal said. “Just as the last decade was greatly influenced by OSFP, the next decade will be greatly influenced by XPO,” Ullal said. “And remember, 99% of the optical market today that we connect to is all pluggable optics. So this is a very crucial invention and innovation, not just for Arista, but the industry at large.” Enterprise AI: Calm before the storm? When it comes to AI for enterprise network customers, Arista’s Ullal says it’s just getting started. The company is seeing a shift from AI training toward more AI inference, “which means you don’t always need the GPU,” Ullal said. “You’re going to have high-end CPUs, and you’re going to have a smaller set of parameters and tokens to manage, and you’re going to have specific agentic AI use cases and applications. We’re seeing very, very early trials and stages. Nothing super big yet.” Some customers are deploying clusters that are “more inference-based, more agentic AI, edge, inference-based as well,” Ullas said. “I think we’ll see more of that. This is the calm before the storm, if you will. As AI gets more distributed, I think it doesn’t need GPUs alone. It’s going to need more high-performance compute… I think it’s gonna take a couple of years to fully happen.”

Lumen advances cloud networking vision with $475M Alkira buy
Lumen puts its total addressable market at approximately $70 billion once Alkira’s international and cloud-to-cloud coverage is included. “Alkira is a bull’s eye in terms of strategic alignment and value creation,” Johnson said. “For Lumen, we expect it to dramatically accelerate our road map execution from years to months.” How the architecture works Alkira operates as a cloud-native, carrier-agnostic control plane. Rather than relying on physical hardware at each interconnection point, it uses a virtual port model that lets enterprises design, deploy and manage network connectivity across clouds, data centers and on-premises environments through a single interface. Alkira is distinct from Lumen’s existing Project Berkeley, which introduces fabric ports for building-to-cloud on-ramp connectivity. “Fabric ports is about enabling building on-prem to be able to connect to the cloud and to be able to grow those services in a cloud economic way,” Johnson said. “The Alkira platform really focuses on the East-West interconnect. So that’s data center-to-data center, cloud-to-cloud, so they operate with more of a virtual port kind of a model, and it’s better together.” Lumen’s Multi-Cloud Gateway bridges the two domains, enabling customers to connect any cloud and any data center over Lumen’s private network. After close, Multi-Cloud Gateway and Alkira together are intended to give customers a single control plane for routing, policy and security across both north-south and east-west connectivity.

NNPC advances rehab, expansion plans for idled refineries
Nigeria National Petroleum Corp. Ltd. (NNPC) has entered a memorandum of understanding (MOU) with China-based Sanjiang Chemical Co. Ltd. and Xinganchen (Fuzhou) Industrial Park Operation and Management Co. Ltd. for collaboration via a potential technical equity partnership to support ongoing rehabilitation and expansion plans at two of its currently idled in-country refining complexes. Announced in early May, the MOU’s proposed framework covers unspecified remaining rehabilitation works at subsidiary Warri Refining & Petrochemical Co. Ltd.’s (WRPC) 125,000-b/sd refinery in Nigeria’s Delta State and Port Harcourt Refining Co. Ltd.’s (PHRC) 60,000-b/sd hydroskimming refinery at Alesa-Eleme near Port Harcourt in Rivers State, NNPC said. Alongside operating and maintenance activities to help the sites achieve best-in-class, sustainable performance, the MOU also outlines proposed expansions and upgrades at both refineries to enable production of cleaner, higher-valued products, according to the company. While NNPC did not clarify the nature of expansion and upgrading plans for either of the refining sections of the sites, the operator said the potential collaboration with Sanjiang Chemical and and Xinganchen (Fuzhou) Industrial Park also would weigh options for expanding the two complex’s petrochemical capabilities, as well as future development of co-located, gas-based industrial hubs at the two locations. NNPC said formal signing of the MOU follows more than 6 months of technical and management discussions with the two Chinese firms to develop a roadmap for restoring sustained, high-performance manufacturing operations at both sites. The MOU comes as part of NNPC’s broader mission to identify potential privately held technical equity partners to help support rehabilitation and expansion of its existing but nonoperational refining infrastructure, which ideally would include a willingness to evaluate opportunities for adding co-located petrochemical production and gas-based industries at the sites, the operator said. The agreement with Sanjiang Chemical and and Xinganchen (Fuzhou) Industrial Park follows NNPC’s announcement earlier

OTC speakers say Venezuela reopening hinges on stability, legal clarity
The conversation comes as the Trump administration continues easing sanctions and encouraging American operators to re-engage with Venezuela’s oil and gas sector. Signs are growing that major international energy companies are reassessing opportunities in the country. ExxonMobil and ConocoPhillips have recently dispatched technical teams to evaluate oilfield infrastructure and upstream prospects, while Gulf Coast refiners have already increased imports of Venezuelan heavy crude. Panelists said the central question facing US energy companies is no longer whether Venezuela will reopen, but whether the conditions, pace, and overall risk profile of that reopening are sufficient to support large-scale, long-term capital investment. Speakers noted that Venezuela’s appeal extends far beyond short-term political change. The country holds one of the world’s largest and most diverse hydrocarbon resource bases, including extra-heavy crude in the Orinoco Belt, conventional light and medium oil, and significant offshore natural gas resources. The opportunity lies not only in the size of the resource base, but also in the long-term development potential, the panelists said. However, years of underinvestment, deteriorating infrastructure, and labor losses mean rebuilding the sector will require significant technical expertise and sustained capital commitments. Oilfield service companies are expected to play an important role if activity accelerates, particularly in offshore gas, heavy oil upgrading, drilling services, and infrastructure rehabilitation. Recent reports indicate service providers have already begun reactivating rigs and equipment stored in Venezuela in anticipation of renewed activity. Speakers emphasized that investors are seeking stable policies and durable legal frameworks before committing capital at scale. Trust in Venezuela’s legal and regulatory system remains weak following years of expropriations and contract disputes. Companies must evaluate not only Venezuela’s domestic political outlook, but also the broader geopolitical dynamics involving the US and China, Borrego noted. China’s long-standing investments and influence in Venezuela’s energy sector were referenced as an important

HPE bolsters autonomous network operations for Mist, Aruba Central
Outside of the wireless realm, HPE has added the ability to autonomously fix VLAN configuration errors in the access layer to prevent blackholing of client traffic and detect/remediate unauthorized DHCP servers. The idea is to mitigate potential external security risks and prevent end user connectivity disruptions, according to a blog post penned by Selena Mosley, HPE Marvis product marketing manager. “A rogue DHCP server—often introduced unintentionally through a BYOD device—can misassign IP addresses and take down entire areas. Marvis detects the anomaly, traces it to the exact switch port, and can automatically contain it, reducing blast radius and restoring service quickly,” Mosley wrote. “Or consider missing VLANs, a common cause of connected but not working scenarios during day‑0 or day‑2 changes. Marvis correlates client telemetry, configuration state, and Marvis Minis validations to identify the mismatch and either remediate automatically or guide the operator with a single action. In each case, the outcome is the same: fewer escalations, faster resolution, and consistent application experience,” Mosley wrote.

S&P Global: Oil markets face ‘double depletion’
Global oil markets are entering a precarious phase marked by a ‘double depletion’ dynamic, in which a sharp contraction in demand is occurring simultaneously with an unprecedented drawdown in crude inventories, according to a recent analysis from S&P Global Energy. These signs indicate the full impact of the current supply disruption—described as the largest in history—has not yet fully materialized, S&P said. Stay updated on oil price volatility, shipping disruptions, LNG market analysis, and production output at OGJ’s Iran war content hub. Oil-demand drop accelerates in second quarter Global liquids demand is projected to fall in second-quarter 2026 in what could be the sharpest contraction outside of the COVID-19 pandemic. For the full year, demand growth is expected to lag 2025 levels, reflecting weakened consumption across major economies. “Oil demand is currently experiencing the sharpest fall ever apart from the 2020 COVID-19 experience, with total liquids demand in the second quarter of 2026 projected to be nearly 5 million b/d less than a year earlier,” S&P Global Energy said, adding that full-year 2026 liquids demand growth is now expected to fall short of 2025 levels by nearly 2 million b/d. At the same time, global crude inventories declined by nearly 200 million bbl in April alone, equivalent to a draw rate of about 6.6 million b/d. The second quarter is now on track to post the largest quarterly inventory draw on record, averaging about 5.5 million b/d. “While there have been significant impacts to date, the oil market has remained somewhat cushioned from the full impact of the loss of 15 million b/d in supply,” said Jim Burkhard, vice-president and global head of crude oil research at S&P Global Energy. “That the cumulative supply loss is now approaching 1 billion bbl is a staggering figure that inventories cannot cover indefinitely.

Equinor brings Eirin field online, exporting gas to Europe
@import url(‘https://fonts.googleapis.com/css2?family=Inter:[email protected]&display=swap’); .ebm-page__main h1, .ebm-page__main h2, .ebm-page__main h3, .ebm-page__main h4, .ebm-page__main h5, .ebm-page__main h6 { font-family: Inter; } body { line-height: 150%; letter-spacing: 0.025em; } button, .ebm-button-wrapper { font-family: Inter; } .label-style { text-transform: uppercase; color: var(–color-grey); font-weight: 600; font-size: 0.75rem; } .caption-style { font-size: 0.75rem; opacity: .6; } #onetrust-pc-sdk [id*=btn-handler], #onetrust-pc-sdk [class*=btn-handler] { background-color: #c19a06 !important; border-color: #c19a06 !important; } #onetrust-policy a, #onetrust-pc-sdk a, #ot-pc-content a { color: #c19a06 !important; } #onetrust-consent-sdk #onetrust-pc-sdk .ot-active-menu { border-color: #c19a06 !important; } #onetrust-consent-sdk #onetrust-accept-btn-handler, #onetrust-banner-sdk #onetrust-reject-all-handler, #onetrust-consent-sdk #onetrust-pc-btn-handler.cookie-setting-link { background-color: #c19a06 !important; border-color: #c19a06 !important; } #onetrust-consent-sdk .onetrust-pc-btn-handler { color: #c19a06 !important; border-color: #c19a06 !important; } Equinor ASA has brought Eirin field online and is now exporting gas to Europe via the Gina Krog and Sleipner A platforms in the North Sea. Previously deemed uncommercial, Eirin field was reassessed in 2023 following Russia’s invasion of Ukraine and the need for more diverse energy sources, Equinor said in a release May 5. The operator submitted a plan for development and operation of the Norwegian North Sea gas field to the Ministry of Petroleum and Energy in 2023. The plan was approved in January 2024. Recoverable reserves in the field, which lies 250 km west of Stavanger in water depth of 120 m, are estimated at 27.6 MMboe, including 3 billion standard cu m of natural gas. The field was developed as a subsea tieback and is expected to extend production from the Gina Krog platform by 7 years to 2036. The gas is exported via Sleipner A, a key hub for Norwegian gas exports to Europe. Gina Krog was electrified in 2023, bringing CO2 emissions for the field to about 3 kg CO2 per bbl produced (oil equivalents). Equinor is operator of the licence with 58.7% interest. ORLEN Upstream Norway AS holds the

‘If this isn’t the time to grow:’ Diamondback lifts 2026 production, capex targets
To fund the additional activity, executives recalibrated the 2026 capex budget to about $3.9 billion, up from $3.6-3.9 billion. The plan, they told analysts, is to bring online some of the company’s inventory of drilled-but-uncompleted (DUC) wells this quarter before rebuilding the DUC count to about 200 by yearend. Maintaining oil production at 521,000 b/d for the year would grow Diamondback’s output nearly 5% higher than 2025. It also would produce a windfall for the company’s coffers: Van’t Hof and his team now are forecasting Diamondback’s 2026 adjusted free cash flow will top $8.3 billion compared with the February estimate of $4.7 billion. Van’t Hof’s commentary and Diamondback’s plans are the most aggressive so far from leaders of publicly traded exploration and production companies during the first-quarter earnings season. Executives at Chevron Corp., ConocoPhillips and ExxonMobil Corp. were more cautious after their reports last week, saying they’re not willing—or at least not yet—to significantly ramp production because of the uncertainty around the situation in the Middle East and the possible resumption of supply from Gulf nations. Diamondback’s plans now call for the addition of 2-3 rigs that will allow the operator to ramp up Midland basin Barnett assets as well as a fifth completion crew. But Van’t Hof also told analysts his team isn’t ready to adjust its mid-cycle pricing assumptions because of the Iran war. Instead, he said, he’s more focused on positioning Diamondback as a low-cost producer with plenty of inventory because “there’s certainly a case to be made for energy security becoming a much more important thing.” “Wearing my oil hat, that probably means more storage, more landed storage versus storage that you can buy […] somewhere that’s in a riskier geopolitical area,” he added. “I think that means the US barrel is more important than it’s

EIA: US crude inventories down 6.2 million bbl
US crude oil inventories for the week ended Apr. 24, excluding the Strategic Petroleum Reserve, decreased by 6.2 million bbl from the previous week, according to data from the US Energy Information Administration (EIA). At 459.5 million bbl, US crude oil inventories are about 1% above the 5-year average for this time of year, the EIA report indicated. EIA said total motor gasoline inventories decreased by 6.1 million bbl from last week and are 2% below the 5-year average for this time of year. Finished gasoline inventories and blending components inventories both decreased last week. Distillate fuel inventories decreased by 4.5 million bbl last week and are about 11% below the 5-year average for this time of year. Propane-propylene inventories decreased by 1.1 million bbl from last week and are 62% above the 5-year average for this time of year, EIA said. US crude oil refinery inputs averaged 16.1 million b/d for the week ended Apr. 24, 85,000 b/d more than the previous week’s average. Refineries operated at 89.6% of capacity. Gasoline production decreased, averaging 9.8 million b/d. Distillate fuel production decreased, averaging 4.9 million b/d. US crude oil imports averaged 5.8 million b/d, down 329,000 b/d from the previous week. Over the last 4 weeks, crude oil imports averaged 5.9 million b/d, 0.7% more than the same 4-week period last year. Total motor gasoline imports averaged 344,000 b/d. Distillate fuel imports averaged 126,000 b/d.

ExxonMobil posts $4.2-billion first-quarter earnings amid Middle East disruptions
Exxon Mobil Corp. reported first-quarter 2026 earnings of $4.2 billion, according to results released May 1. Earnings totaled $4.9 billion excluding identified items, and $8.8 billion when also excluding unfavorable estimated timing effects. First-quarter earnings declined from $7.7 billion in the same period of 2025. However, earnings excluding identified items and timing effects were up from $7.6 billion a year earlier. Unfavorable estimated timing effects totaled $3.9 billion, reflecting the mismatch between the valuation of financial derivatives and the associated physical transactions, resulting in a timing difference in earnings that unwinds in subsequent periods. Identified items of $0.7 billion were attributed to losses on settled financial hedges that were not offset by the associated physical shipments due to Middle East supply disruptions. Cash flow from operations was $8.7 billion, or $13.8 billion excluding margin postings, which primarily fluctuate with the fair value of underlying derivatives. Free cash flow totaled $2.7 billion. Shareholder distributions reached $9.2 billion, including $4.3 billion in dividends and $4.9 billion in share repurchases, in line with plans to repurchase $20 billion of shares in 2026, assuming reasonable market conditions. Exxon’s cash capital expenditures totaled $6.2 billion for the quarter, consistent with the company’s full-year guidance of $27-29 billion. Iran war disruptions Chairman and chief executive officer Darren Woods emphasized the company’s underlying performance, stating that results excluding timing effects reflect the strength of the company’s advantaged portfolio. Stay updated on oil price volatility, shipping disruptions, LNG market analysis, and production output at OGJ’s Iran war content hub. During the earnings call, Woods said markets have not yet fully reflected the impact of Middle East supply disruptions, as inventories and strategic reserves have temporarily offset losses. He said even if the Strait reopens, it could take 1-2 months for flows to normalize, with additional demand from inventory

Equinor signs FEED agreement for Bay du Nord FPSO
@import url(‘https://fonts.googleapis.com/css2?family=Inter:[email protected]&display=swap’); .ebm-page__main h1, .ebm-page__main h2, .ebm-page__main h3, .ebm-page__main h4, .ebm-page__main h5, .ebm-page__main h6 { font-family: Inter; } body { line-height: 150%; letter-spacing: 0.025em; } button, .ebm-button-wrapper { font-family: Inter; } .label-style { text-transform: uppercase; color: var(–color-grey); font-weight: 600; font-size: 0.75rem; } .caption-style { font-size: 0.75rem; opacity: .6; } #onetrust-pc-sdk [id*=btn-handler], #onetrust-pc-sdk [class*=btn-handler] { background-color: #c19a06 !important; border-color: #c19a06 !important; } #onetrust-policy a, #onetrust-pc-sdk a, #ot-pc-content a { color: #c19a06 !important; } #onetrust-consent-sdk #onetrust-pc-sdk .ot-active-menu { border-color: #c19a06 !important; } #onetrust-consent-sdk #onetrust-accept-btn-handler, #onetrust-banner-sdk #onetrust-reject-all-handler, #onetrust-consent-sdk #onetrust-pc-btn-handler.cookie-setting-link { background-color: #c19a06 !important; border-color: #c19a06 !important; } #onetrust-consent-sdk .onetrust-pc-btn-handler { color: #c19a06 !important; border-color: #c19a06 !important; } <!–> Equinor has signed a front-end engineering and design (FEED) agreement with BW Offshore for the Bay du Nord development offshore Newfoundland and Labrador, Canada. The agreement formalizes the next phase of the project following BW Offshore’s selection as preferred FPSO bidder, BW Offshore said in a release Apr. 29. A final investment decision on the project is expected in 2027. The FEED phase is expected to run through end-2026 and will be used to mature the FPSO design, finalizing the project execution plan and delivery schedule, progressing commercial and contractual alignment, including selection of major subcontractors and vendors towards a firm offer to Equinor. BW Offshore has established a local office in St. John’s, Newfoundland and Labrador that is expected to officially open in early June. ]–> Illustration from Equinor. <!–> ]–> <!–> April 7, 2022 ]–> Bay du Nord oil project The Bay du Nord project is a series of oil discoveries in the Flemish Pass Basin, about 500 km northeast of St. John’s. Through an estimated investment of about $14 billion (Can.), the project could open a new deepwater basin offshore Canada and create the foundation for future subsea tie-backs, extending activity in

National Grid, Con Edison urge FERC to adopt gas pipeline reliability requirements
The Federal Energy Regulatory Commission should adopt reliability-related requirements for gas pipeline operators to ensure fuel supplies during cold weather, according to National Grid USA and affiliated utilities Consolidated Edison Co. of New York and Orange and Rockland Utilities. In the wake of power outages in the Southeast and the near collapse of New York City’s gas system during Winter Storm Elliott in December 2022, voluntary efforts to bolster gas pipeline reliability are inadequate, the utilities said in two separate filings on Friday at FERC. The filings were in response to a gas-electric coordination meeting held in November by the Federal-State Current Issues Collaborative between FERC and the National Association of Regulatory Utility Commissioners. National Grid called for FERC to use its authority under the Natural Gas Act to require pipeline reliability reporting, coupled with enforcement mechanisms, and pipeline tariff reforms. “Such data reporting would enable the commission to gain a clearer picture into pipeline reliability and identify any problematic trends in the quality of pipeline service,” National Grid said. “At that point, the commission could consider using its ratemaking, audit, and civil penalty authority preemptively to address such identified concerns before they result in service curtailments.” On pipeline tariff reforms, FERC should develop tougher provisions for force majeure events — an unforeseen occurence that prevents a contract from being fulfilled — reservation charge crediting, operational flow orders, scheduling and confirmation enhancements, improved real-time coordination, and limits on changes to nomination rankings, National Grid said. FERC should support efforts in New England and New York to create financial incentives for gas-fired generators to enter into winter contracts for imported liquefied natural gas supplies, or other long-term firm contracts with suppliers and pipelines, National Grid said. Con Edison and O&R said they were encouraged by recent efforts such as North American Energy Standard

US BOEM Seeks Feedback on Potential Wind Leasing Offshore Guam
The United States Bureau of Ocean Energy Management (BOEM) on Monday issued a Call for Information and Nominations to help it decide on potential leasing areas for wind energy development offshore Guam. The call concerns a contiguous area around the island that comprises about 2.1 million acres. The area’s water depths range from 350 meters (1,148.29 feet) to 2,200 meters (7,217.85 feet), according to a statement on BOEM’s website. Closing April 7, the comment period seeks “relevant information on site conditions, marine resources, and ocean uses near or within the call area”, the BOEM said. “Concurrently, wind energy companies can nominate specific areas they would like to see offered for leasing. “During the call comment period, BOEM will engage with Indigenous Peoples, stakeholder organizations, ocean users, federal agencies, the government of Guam, and other parties to identify conflicts early in the process as BOEM seeks to identify areas where offshore wind development would have the least impact”. The next step would be the identification of specific WEAs, or wind energy areas, in the larger call area. BOEM would then conduct environmental reviews of the WEAs in consultation with different stakeholders. “After completing its environmental reviews and consultations, BOEM may propose one or more competitive lease sales for areas within the WEAs”, the Department of the Interior (DOI) sub-agency said. BOEM Director Elizabeth Klein said, “Responsible offshore wind development off Guam’s coast offers a vital opportunity to expand clean energy, cut carbon emissions, and reduce energy costs for Guam residents”. Late last year the DOI announced the approval of the 2.4-gigawatt (GW) SouthCoast Wind Project, raising the total capacity of federally approved offshore wind power projects to over 19 GW. The project owned by a joint venture between EDP Renewables and ENGIE received a positive Record of Decision, the DOI said in

Biden Bars Offshore Oil Drilling in USA Atlantic and Pacific
President Joe Biden is indefinitely blocking offshore oil and gas development in more than 625 million acres of US coastal waters, warning that drilling there is simply “not worth the risks” and “unnecessary” to meet the nation’s energy needs. Biden’s move is enshrined in a pair of presidential memoranda being issued Monday, burnishing his legacy on conservation and fighting climate change just two weeks before President-elect Donald Trump takes office. Yet unlike other actions Biden has taken to constrain fossil fuel development, this one could be harder for Trump to unwind, since it’s rooted in a 72-year-old provision of federal law that empowers presidents to withdraw US waters from oil and gas leasing without explicitly authorizing revocations. Biden is ruling out future oil and gas leasing along the US East and West Coasts, the eastern Gulf of Mexico and a sliver of the Northern Bering Sea, an area teeming with seabirds, marine mammals, fish and other wildlife that indigenous people have depended on for millennia. The action doesn’t affect energy development under existing offshore leases, and it won’t prevent the sale of more drilling rights in Alaska’s gas-rich Cook Inlet or the central and western Gulf of Mexico, which together provide about 14% of US oil and gas production. The president cast the move as achieving a careful balance between conservation and energy security. “It is clear to me that the relatively minimal fossil fuel potential in the areas I am withdrawing do not justify the environmental, public health and economic risks that would come from new leasing and drilling,” Biden said. “We do not need to choose between protecting the environment and growing our economy, or between keeping our ocean healthy, our coastlines resilient and the food they produce secure — and keeping energy prices low.” Some of the areas Biden is protecting

Biden Admin Finalizes Hydrogen Tax Credit Favoring Cleaner Production
The Biden administration has finalized rules for a tax incentive promoting hydrogen production using renewable power, with lower credits for processes using abated natural gas. The Clean Hydrogen Production Credit is based on carbon intensity, which must not exceed four kilograms of carbon dioxide equivalent per kilogram of hydrogen produced. Qualified facilities are those whose start of construction falls before 2033. These facilities can claim credits for 10 years of production starting on the date of service placement, according to the draft text on the Federal Register’s portal. The final text is scheduled for publication Friday. Established by the 2022 Inflation Reduction Act, the four-tier scheme gives producers that meet wage and apprenticeship requirements a credit of up to $3 per kilogram of “qualified clean hydrogen”, to be adjusted for inflation. Hydrogen whose production process makes higher lifecycle emissions gets less. The scheme will use the Energy Department’s Greenhouse Gases, Regulated Emissions and Energy Use in Transportation (GREET) model in tiering production processes for credit computation. “In the coming weeks, the Department of Energy will release an updated version of the 45VH2-GREET model that producers will use to calculate the section 45V tax credit”, the Treasury Department said in a statement announcing the finalization of rules, a process that it said had considered roughly 30,000 public comments. However, producers may use the GREET model that was the most recent when their facility began construction. “This is in consideration of comments that the prospect of potential changes to the model over time reduces investment certainty”, explained the statement on the Treasury’s website. “Calculation of the lifecycle GHG analysis for the tax credit requires consideration of direct and significant indirect emissions”, the statement said. For electrolytic hydrogen, electrolyzers covered by the scheme include not only those using renewables-derived electricity (green hydrogen) but

Xthings unveils Ulticam home security cameras powered by edge AI
Join our daily and weekly newsletters for the latest updates and exclusive content on industry-leading AI coverage. Learn More Xthings announced that its Ulticam security camera brand has a new model out today: the Ulticam IQ Floodlight, an edge AI-powered home security camera. The company also plans to showcase two additional cameras, Ulticam IQ, an outdoor spotlight camera, and Ulticam Dot, a portable, wireless security camera. All three cameras offer free cloud storage (seven days rolling) and subscription-free edge AI-powered person detection and alerts. The AI at the edge means that it doesn’t have to go out to an internet-connected data center to tap AI computing to figure out what is in front of the camera. Rather, the processing for the AI is built into the camera itself, and that sets a new standard for value and performance in home security cameras. It can identify people, faces and vehicles. CES 2025 attendees can experience Ulticam’s entire lineup at Pepcom’s Digital Experience event on January 6, 2025, and at the Venetian Expo, Halls A-D, booth #51732, from January 7 to January 10, 2025. These new security cameras will be available for purchase online in the U.S. in Q1 and Q2 2025 at U-tec.com, Amazon, and Best Buy. The Ulticam IQ Series: smart edge AI-powered home security cameras Ulticam IQ home security camera. The Ulticam IQ Series, which includes IQ and IQ Floodlight, takes home security to the next level with the most advanced AI-powered recognition. Among the very first consumer cameras to use edge AI, the IQ Series can quickly and accurately identify people, faces and vehicles, without uploading video for server-side processing, which improves speed, accuracy, security and privacy. Additionally, the Ulticam IQ Series is designed to improve over time with over-the-air updates that enable new AI features. Both cameras

Intel unveils new Core Ultra processors with 2X to 3X performance on AI apps
Join our daily and weekly newsletters for the latest updates and exclusive content on industry-leading AI coverage. Learn More Intel unveiled new Intel Core Ultra 9 processors today at CES 2025 with as much as two or three times the edge performance on AI apps as before. The chips under the Intel Core Ultra 9 and Core i9 labels were previously codenamed Arrow Lake H, Meteor Lake H, Arrow Lake S and Raptor Lake S Refresh. Intel said it is pushing the boundaries of AI performance and power efficiency for businesses and consumers, ushering in the next era of AI computing. In other performance metrics, Intel said the Core Ultra 9 processors are up to 5.8 times faster in media performance, 3.4 times faster in video analytics end-to-end workloads with media and AI, and 8.2 times better in terms of performance per watt than prior chips. Intel hopes to kick off the year better than in 2024. CEO Pat Gelsinger resigned last month without a permanent successor after a variety of struggles, including mass layoffs, manufacturing delays and poor execution on chips including gaming bugs in chips launched during the summer. Intel Core Ultra Series 2 Michael Masci, vice president of product management at the Edge Computing Group at Intel, said in a briefing that AI, once the domain of research labs, is integrating into every aspect of our lives, including AI PCs where the AI processing is done in the computer itself, not the cloud. AI is also being processed in data centers in big enterprises, from retail stores to hospital rooms. “As CES kicks off, it’s clear we are witnessing a transformative moment,” he said. “Artificial intelligence is moving at an unprecedented pace.” The new processors include the Intel Core 9 Ultra 200 H/U/S models, with up to

A blueprint for using AI to strengthen democracy
Every few centuries, changes in how information moves reshape how societies govern themselves. The printing press spread vernacular literacy, helping give rise to the Reformation and, eventually, representative government. The telegraph made it possible to administer vast nations like the US, accelerating the growth of the modern bureaucratic state. Broadcast media created shared national audiences, which in turn fueled mass democracy. We are now in the early stages of another such shift. Faster than many realize, AI is becoming the primary interface through which we form beliefs and participate in democratic self-governance. If left unchecked, this shift could further strain America’s already fragile institutions. But it could also help address long-standing problems, like lagging civic engagement and deepening polarization. What happens next depends on design choices that are already being made, whether we know it or not. Start with what might be called the epistemic layer—how we come to know things. People are increasingly relying on AI to know what is true, what is happening, and whom to trust. Search is already substantially AI-mediated. The next generation of AI assistants will synthesize information, frame it, and present it with authority. For a growing number of people, asking an AI will become the default way to form views on a candidate, a policy, or a public figure. Whoever controls what these models say therefore has increasing influence over what people believe. Technology has always shaped the way citizens interact with information. But a new problem will soon arise in the form of personal AI agents, which can change not only how people receive information but how they act on it. These systems will conduct research, draft communications, highlight causes, and lobby on a user’s behalf. They will inform decisions such as how to vote on a ballot measure, which organizations are worth supporting, or how to respond to a government notice. They will, in a meaningful sense, begin to mediate the relationship between individuals and the institutions that govern them.
We’ve already seen with social media what happens when algorithms optimize for engagement over understanding. Platforms do not need to have an explicit political agenda to produce polarization and radicalization. An agent that knows your preferences and your anxieties—one shaped to keep you engaged—poses the same risks. And in this case the risks may be even more difficult to detect, because an agent presents itself as your advocate. It speaks for you, acts on your behalf, and may earn trust precisely through that intimacy. Now zoom out to the collective. AI agents and humans could soon participate in the same forums, where it may be impossible to tell them apart. Even if every individual AI agent were well-designed and aligned with its user’s interests, the interactions of millions of agents could produce outcomes that no individual wanted or chose. For example, research shows that agents displaying no individual bias can still generate collective biases at scale. And setting aside what agents do to each other, there is what they do for their users. A public sphere in which everyone has a personalized agent attuned to their existing views is not, in aggregate, a public sphere at all. It is a collection of private worlds, each internally coherent but collectively inhospitable to the kind of shared deliberation that democracy requires.
Taken together, these three transformations—in how we know, how we act, and how we engage in collective governance—amount to a fundamental change in the texture of citizenship. In the near future, people will form their political views through AI filters, exercise their civic agency through AI agents, and participate in institutions and public discussions that are themselves shaped by the interactions of millions of such agents. Today’s democracy is not ready for this. Our institutions were designed for a world in which power was exercised visibly, information traveled slowly enough to be contested, and reality felt more shared, if imperfectly. All of this was already fraying long before generative AI arrived. And yet this need not be a story of decline. Avoiding that outcome requires us to design for something better. On the informational layer, AI companies must ramp up existing efforts to ensure that models’ outputs are truthful. They should also explore some promising early findings that AI models can help reduce polarization. A recent field evaluation of AI-generated fact checks on X found that people with a variety of political viewpoints deemed AI-written notes more helpful than human-written ones. The paper is yet to be peer-reviewed, but that is a potentially revolutionary finding: AI-assisted fact-checking may be able to achieve the kind of cross-partisan credibility that has eluded most manual human efforts. Greater understanding of and transparency about how models make these assertions and prioritize sources in the process could help build further public trust. On the agentic layer, we need ways to evaluate whether AI agents faithfully represent their users. An agent must never have an agenda of its own or misrepresent its user’s views—a technically daunting requirement in domains where users may have not explicitly stated any preferences. But faithful representation also cannot become an accessory to motivated reasoning. An agent that refuses to present uncomfortable information, that shields its user from ever questioning prior beliefs or fails to adjust to a change of heart, is not acting in the person’s best interest. Finally, on the institutional level, policymakers should hurry to harness AI’s potential to make governance more responsive and legitimate. Several states and localities are already using AI-mediated platforms to conduct democratic deliberation at scale, building on research showing that AI mediators can help citizens find common ground. As agents become increasingly common participants in public input processes—and there is already evidence that bots are skewing those processes—identity verification for both humans and their agentic proxies must be built in from the start. What is needed is a new generation of democratic infrastructure, technological and institutional, built for the world that is actually here. Failing to design for democratic outcomes, in a domain this consequential, means designing for something else. And the history of unaccountable power does not leave much room for optimism about what that something else tends to be. Andrew Sorota and Josh Hendler lead work on AI and democracy at the Office of Eric Schmidt.

Week one of the Musk v. Altman trial: What it was like in the room
This story originally appeared in The Algorithm, our weekly newsletter on AI. To get stories like this in your inbox first, sign up here. Two of the most powerful people in AI—Sam Altman and Elon Musk—began their face-off in court in Oakland, California, last week. Musk is suing OpenAI, alleging that the millions he spent to fund it around a decade ago were meant for a nonprofit, not a corporation, and that the company has reneged on that mission since. The stakes are high—even a partial win for Musk could set OpenAI back as it reportedly plans to go public this year. But most of the attention comes from the spectacle of a feud on X now playing out in federal court. “Cringey texts, raw diary entries, and endless scheming behind the founding and growth of OpenAI are expected to come to light,” my colleague Michelle Kim wrote before it began. And the trial unfolds as the cultural backlash against AI swells; some of the signs held by protesters outside the courthouse suggest that to a significant number of people, whatever the outcome of Musk v. Altman, we all lose. Most of us have had to observe the trial from afar, but Michelle, who also happens to be a lawyer, has been in court each day. I caught up with her to learn what’s unfolded thus far and what might come next.
Can you give us the overview of what this case is actually about? What exactly is being decided, and who is favored right now? Elon Musk is arguing that Sam Altman and OpenAI president Greg Brockman have breached the company’s charitable trust by effectively converting OpenAI into a for-profit company. Musk alleges that is not what they promised him in the company’s early days. He has asked for several remedies, like a crazy amount of damages and removing Sam Altman. But the main remedy he wants is unwinding OpenAI’s restructuring. [In October 2025 OpenAI struck deals with the attorneys general of California and Delaware that would essentially allow its nonprofit portion to have less day-to-day control of OpenAI. It’s a compromise from what OpenAI originally proposed, but Musk still wants to stop it.]
OpenAI argues that Elon Musk actually agreed to have the company operate a for-profit arm, because he knew building AI is very expensive. So it’s about proving what Musk knew, what he didn’t know, and whether he really was deceived by Altman and Brockman. There’s a big debate about when exactly Musk found out about this alleged misconduct. Musk founded OpenAI with Altman and Brockman in 2015, and he brought the suit in 2024. There’s a statute of limitations for charitable trust claims; you need to have brought a claim within three to four years after you find out about the alleged misconduct. So Musk tries to paint a picture that back in the day he was a little suspicious, but that it was really only in 2022 that he realized OpenAI was no longer committed to its original charitable mission, and that he had been scammed. It’s only the first week of trial, but I’m not sure Musk has proved this to the judge and jury. What were some standout moments thus far? At one point one of Elon Musk’s lawyers said, “We could all die as a result of AI.” I think a lot of the people in the room were really shaken by this comment, and the judge told Musk’s lawyer: You talk about all these safety risks that OpenAI has when building AI, but Musk is also creating a company that’s in the same exact space. She basically said, I’m sure there’s plenty of people who also don’t want to put the future of humanity in Elon Musk’s hands. And then the lawyers just kept going on and on about the catastrophic risks of AI and whether Elon Musk or OpenAI was in the better position to steward AI safety. And the judge sort of snapped. She said very sternly that this trial was not about whether or not artificial intelligence has damaged humanity. And I thought that was a really striking standout moment of the trial that pointed at how even though it is technically just about whether Elon Musk was really deceived by OpenAI, it’s also become a huge discussion about AI safety and some of the practices that the labs are engaging in when building AI. Can you give us a look behind the curtain at how getting into this trial works? There are tons of reporters. This is a very high-profile suit, so I have to wake up around 4:30 a.m. and show up to the Oakland courthouse at 6 a.m. sharp to get in line. And on some days, even 6 a.m. doesn’t get you into the courtroom. There are lots of photographers in front of the courthouse, especially on days when you know Musk or Altman and Brockman are present. And there’s also some concerned citizens who want to watch the trial. I usually have to wait, like, two hours in line to get in to be one of the 30 people who claim the unreserved seats in the courtroom. What has it felt like to see Elon Musk testify? How would you describe his demeanor?
He shows up in a crisp black suit. He can be this inflammatory person on X, but in the courtroom, he is calm, cool, collected, and looks very comfortable. He has been in a lot of lawsuits. He knows how to talk to the jury and how to present himself in front of them and the judge. He’s also cracking jokes with his lawyer and even the opposing party’s lawyer and the judge. And he can be witty. There was this one moment when OpenAI’s lawyer was asking Musk a question and sort of fed him an answer. And Musk said “That’s not a leading question, that’s a leading answer.” The judge intervened and said, “You’re not a lawyer, Elon.” And then he was like, “Well, I did take Law 101.” That said, he does get flustered and uncomfortable when OpenAI’s lawyer asks tough, piercing questions. Which he’s been doing. What are the biggest things we’ve learned that weren’t clear in the earlier phases of this case? On the fourth day of the trial, Musk admitted during cross-examination that xAI distills OpenAI’s models to train its own models, which was shocking. Musk followed up by saying that this is standard practice among all the labs now and that xAI wasn’t doing anything beyond what others were already doing. But a lot of the journalists started typing away at their laptops as soon as Musk made this comment. I also learned that there’s just so much scheming among Big Tech executives. You know about it vaguely, but to hear firsthand accounts and read their emails and text messages is fascinating. For example, there was a text message between Musk and Mark Zuckerberg of Meta, where they’re kind of teaming up to stop OpenAI’s restructuring. They’re even trying to make a bid to buy all the assets of OpenAI’s nonprofit. The level of scheming that goes on among these executives is mind-blowing. What happens next?
OpenAI’s president, Greg Brockman, who was meticulously taking notes during some of Elon Musk’s testimony, is expected to testify next week. And Stuart Russell, a computer scientist at UC Berkeley, will testify about AI safety. I’m expecting that to open the floodgates to this crazy discussion about who can be trusted to build AI. A bunch of other high-profile people are expected to testify, like former OpenAI chief scientist Ilya Sutskever, former CTO Mira Murati, and Microsoft CEO Satya Nadella.
The trial is supposed to last around three weeks. The nine jurors will deliver an advisory verdict that guides the judge on how to decide Musk’s claims against OpenAI. The judge doesn’t have to listen to the jury and can decide however she wants. If she decides OpenAI is liable, then she’ll decide what sort of remedies are appropriate. MIT Technology Review will have ongoing coverage of Musk v. Altman until its conclusion. Follow @techreview or @michelletomkim on X for up-to-the-minute reporting.

Tailoring AI solutions for health care needs
In partnership withMayo Clinic Platform The AI market is full of big promises of grand transformation. Health care is a prime target for those promises, beset as it is by financial pressures, labor shortages, and the growing burden of caring for an aging population. AI developers are targeting functions that vary widely, from curing cancer and performing surgery to streamlining routine administrative tasks. The opportunity is genuine, but execution can be difficult. Numerous software vendors have tried to “fix” health care challenges but failed because they misunderstood the environment. “Health care is very complex,” says Steve Bethke, vice president of the solution developer market for Mayo Clinic Platform, which supports the buildout and deployment of digital solutions for health care companies through data-based insights and expert validation. “Solution developers must have a deep focus on clinical and technical capabilities, and then align their solutions to the relevant business impacts. If they miss any dimension, the solution will not be adopted or drive value.” AI applications for health care are proliferating rapidly. The U.S. Food and Drug Administration has approved more than 1,300 AI-enabled medical devices, mostly for interpreting diagnostic images. More than half of these were approved in the past three years, with the earliest dating as far back as 1995. Non-radiological applications carry out tasks as diverse as tracking sleep apnea, analyzing heart rhythms, and planning orthopedic surgeries. AI applications that do not count as medical devices— for example, those that handle scheduling and administrative tasks—are more difficult to track but are also rapidly increasing. AI can help coordinate complex tasks and workflows that are often conventionally managed by whiteboards and sticky notes. Such functions may well outstrip clinical uses in their impact on health systems. A recent survey of technology leaders found that 72% said their top priority for AI was reducing caregiver burden and improving caregiver satisfaction, while over half (53%) cited workflow efficiency and productivity.
Any health care-related application can potentially impact patient care, whether directly or indirectly, and AI apps that are poorly designed or inadequately trained and validated can put patients at risk. Providers recognize that risk: In the same survey, 77% said immature AI tools are a significant barrier to adoption. Regulators and lawmakers are also keeping an eye on the risks as development and adoption burgeon, though the U.S. regulatory picture is still in flux, as a 2024 report to Congress on AI in health care observes. To tackle some of the technical challenges, many health care providers are partnering with application developers to build AI solutions. In a recent study, McKinsey found that 61% of health care organizations intend to pursue partnerships with third-party vendors to develop customized generative AI solutions as a primary strategy as opposed to building them in-house or buying off-the-shelf products.
But health care-specific AI applications must also be tailored to the nuanced clinical needs of medical providers as well as the complex business and regulatory considerations of the wider sector. This is where developers can benefit from working with a partner with a deep understanding of the health care environment to tailor applications to what providers want and need most. Doing so helps to position AI products for maximum impact and value, avoiding the pitfalls unique to the health care environment. Download the report. This content was produced by Insights, the custom content arm of MIT Technology Review. It was not written by MIT Technology Review’s editorial staff. It was researched, designed, and written by human writers, editors, analysts, and illustrators. This includes the writing of surveys and collection of data for surveys. AI tools that may have been used were limited to secondary production processes that passed thorough human review.

Musk v. Altman week 1: Elon Musk says he was duped, warns AI could kill us all, and admits that xAI distills OpenAI’s models
In the first week of the landmark trial between Elon Musk and OpenAI, Musk took the stand in a crisp black suit and tie and argued that OpenAI CEO Sam Altman and president Greg Brockman had deceived him into bankrolling the company. Along the way, he warned that AI could destroy us all and sat through revelations that he had poached OpenAI employees for his own companies. He even confessed, to some audible gasps in the courtroom, that his own AI company, xAI, which makes the chatbot Grok, uses OpenAI’s models to train its own. The federal courthouse in Oakland, California, was packed with armies of lawyers carrying boxes of exhibits, journalists typing away at their laptops, and a handful of concerned OpenAI employees. Outside, protesters lined the streets, carrying signs urging people to quit ChatGPT, boycott Tesla, or both. Musk looked calm and comfortable, slipping in the occasional quip in his distinct South African accent. But he also was full of remorse. “I was a fool who provided them free funding to create a startup,” Musk told the jury. He said when he cofounded OpenAI in 2015 with Altman and Brockman, he was donating to a nonprofit developing AI for the benefit of humanity, not to make the executives rich. “I gave them $38 million of essentially free funding, which they then used to create what would become an $800 billion company,” he said. Musk is asking the court to remove Altman and Brockman from their roles and to unwind the restructuring that allowed OpenAI to operate a for-profit subsidiary. The outcome of the trial could upend OpenAI’s race toward an IPO at a valuation approaching $1 trillion. Meanwhile, xAI is expected to go public as a part of Musk’s rocket company SpaceX as early as June, at a target valuation of $1.75 trillion.
This week’s testimony revolved around a central question of the trial: why Musk is suing OpenAI. Musk argued he was trying to save OpenAI’s mission to develop AI safely by restoring the company to its original nonprofit structure. OpenAI’s lawyer, William Savitt, who once represented Musk and his electric-car company Tesla, countered that Musk was “never committed to OpenAI being a nonprofit” and instead was suing to undermine his competitor. Who is the steward of AI safety? During his direct examination early in the week, Musk painted himself as a longtime advocate of AI safety. He said he cofounded OpenAI to create a “counterbalance to Google,” which was leading the AI race at the time. He said that when he asked Google cofounder Larry Page what happens if AI tries to wipe out humanity, Page told him, “That will be fine as long as artificial intelligence survives.”
“The worst-case scenario is a Terminator situation where AI kills us all,” Musk later told the jury. Savitt stood at the lectern and argued that Musk was not a “paladin of safety and regulation.” As he cross-examined Musk in his sharp, surgical cadence, Savitt pointed out that xAI sued the state of Colorado in April over an AI law designed to prevent algorithmic discrimination. Musk’s lawyer, Steven Molo, sprang to his feet to object. He asked the judge if he, too, could weigh in on ChatGPT’s safety record. The lawyers then entered a heated debate about who was the true guardian of AI safety. The sparring continued the next morning. “We all could die as a result of artificial intelligence!” said Molo, suggesting that OpenAI could not be trusted to build AI safely. “Despite these risks, your client is creating a company that’s in the exact space,” Judge Yvonne Gonzalez Rogers said sternly, referring to xAI. “I suspect there’s plenty of people who don’t want to put the future of humanity in Mr. Musk’s hands.” When the lawyers began talking over each other, the judge snapped. “This is not a trial on whether or not artificial intelligence has damaged humanity,” she said. When did Musk think he was being duped? As Savitt continued to cross-examine Musk, he pressed on the idea that Musk had never been committed to keeping OpenAI a nonprofit. He also claimed that Musk waited too long to sue OpenAI, filing after the statute of limitations ran out.
Musk explained why he sued in 2024 rather than earlier, describing “three phases” in his views of OpenAI. In phase one, he was “enthusiastically supportive” of the company.” In phase two, “I started to lose confidence that they were telling me the truth,” he said. In phase three, “I’m sure they’re looting the nonprofit.” In 2017, Musk and other OpenAI cofounders discussed creating a for-profit subsidiary to raise enough capital to build artificial general intelligence—powerful AI that can compete with humans on most cognitive tasks. Musk wanted a majority interest in the subsidiary and the right to choose a majority of the board members. He also pitched having Tesla acquire OpenAI. (He left OpenAI in 2018.) “I was not opposed to there being a small for-profit that provides funding to the nonprofit,” he told the jury, “as long as the tail didn’t wag the dog.” But it was only in late 2022, Musk testified, that he “lost trust in Altman” and his commitment to keeping the company a nonprofit. The key moment came, he said, when he learned that Microsoft would invest $10 billion in OpenAI. “I texted Sam Altman, ‘What the hell is going on? This is a bait and switch,’” he told the jury. Microsoft would give $10 billion only if it expected “a very big financial return,” he said. Is Musk just trying to kill competition? But Savitt argued that Musk was really suing to undermine OpenAI as a competitor to his empire of tech companies. While he was on the board of OpenAI, Musk was also running Tesla and his brain-implant company, Neuralink. He founded xAI in 2023. Savitt pulled up an email that Musk had sent to a Tesla vice president in 2017 after hiring Andrej Karpathy, a founding member of OpenAI, to work at Tesla.“The OpenAI guys are gonna want to kill me. But it had to be done,” he wrote. When asked about it, Musk was flustered. He claimed Karpathy had already decided to leave OpenAI when he recruited him to work at Tesla. “I believe it’s a free world,” he said.Savitt pulled up another email that Musk sent to a cofounder at Neuralink in 2017. He wrote that they could “hire independently or directly from OpenAI.” When pressed about it, he sounded frazzled. “It’s a free country,” he said. “I can’t restrict their ability to hire people from other companies.”
Savitt also pointed out that Tesla, SpaceX, Neuralink, and X were socially beneficial for-profit companies, like OpenAI. He stressed that xAI was also a closed-source, for-profit company. But Musk claimed that xAI was not a real competitor to OpenAI. “We’re not currently tracking to reach AGI first,” he told the jury.
In fact, Musk admitted that xAI uses OpenAI’s technology. In response to Savitt’s relentless questioning, he said xAI “partly” distills OpenAI’s models. Some people in the courtroom gasped. Distillation is a technique where a smaller AI model is trained to mimic the behavior of larger, more capable models, so it can run faster and more cheaply while performing nearly as well. But OpenAI and other AI companies have pushed back against the practice. In February, OpenAI accused the Chinese AI company DeepSeek of distilling its AI models. In August 2025, Wired reported that Anthropic had blocked OpenAI’s access to Claude for violating the company’s terms of service, which prohibit, among other things, reverse-engineering its services and building competing products. “It is standard practice to use other AIs to validate your AI,” argued Musk.Next week, Stuart Russell, a computer scientist at UC Berkeley, will testify about AI safety. Brockman, who has been taking notes during Musk’s testimony, will also testify. This story is part of MIT Technology Review’s ongoing coverage of the Musk v. Altman trial. Follow @techreview or @michelletomkim on X for up-to-the-minute reporting.

Cyber-Insecurity in the AI Era
Presented byGC Cybersecurity Cybersecurity was already under strain before AI entered the stack. Now, as AI expands the attack surface and adds new complexity, the limits of legacy approaches are becoming harder to ignore. This session from MIT Technology Review’s EmTech AI conference explores why security must be rethought with AI at its core, not layered on after the fact. About the speaker Tarique Mustafa, Cofounder, CEO, and CTO, GC Cybersecurity Tarique Mustafa is Cofounder and CEO/CTO of two AI-powered cybersecurity companies: GCCybersecurity, Inc. and its data compliance spinout, Chorology, Inc. A prolific inventor and internationally recognized authority in knowledge representation, inference calculus, and AI planning, Tarique has spent his career applying autonomously collaborative AI to solve complex, ultra-high-scale challenges across cybersecurity, data security, and compliance — with deep expertise spanning Data Classification, DLP, and DSPM industries. His groundbreaking innovations and multiple USPTO patents have earned him global recognition, including frequent invitations to deliver keynote addresses at prestigious international security conferences and forums.
At GCCybersecurity, Tarique architected the core AI algorithms powering the company’s 4th and 5th generation fully autonomous data leak protection and exfiltration platform — among the most advanced platform of its kind. Prior to founding GCCybersecurity and Chorology, he served as founding CEO/CTO of NexTier Networks, a Silicon Valley provider of award-winning Data Leak Prevention solutions. With over 20 years of technical leadership experience, Tarique has held senior roles at Symantec, DHL Airways IT, MCI WorldCom, EDS, Andes Networks, and Nevis Networks, where he served as Principal Architect and built industry-leading security products leveraging next-generation security monitoring, event correlation, IDS/IPS, and SSL/IPSec technologies. Tarique holds multiple approved and pending patents with the USPTO and has authored numerous research publications spanning Information & Data Security, Computer & Network Security, Software Architecture, Database Technologies, and Artificial Intelligence. A recipient of the prestigious Rotary International Scholarship for doctoral studies in Computer Science at the University of Southern California (USC), Tarique also holds master’s degrees in engineering and computer science from USC, and a bachelor’s degree in mechanical engineering from NED University of Engineering & Technology.

Operationalizing AI for Scale and Sovereignty
Presented by Companies are taking control of their own data to tailor AI for their needs. The challenge lies in balancing ownership with the safe, trusted flow of high‑quality data needed to power reliable insights. This conversation from MIT Technology Review’s EmTech AI conference examines how AI factories unlock new levels of scale, sustainability, and governance—positioning data control as a strategic imperative for governments and enterprises. About the speakers Chris Davidson, Vice President, HPC & AI Customer Solutions, HPE Chris Davidson is Vice President of HPC & AI Customer Solutions at Hewlett Packard Enterprise. He leads HPE’s global strategy for AI Factory solutions and Sovereign AI, working with governments, enterprises, and research institutions to build secure, scalable national- and enterprise-grade AI capabilities. He also directs Product Management and Performance Engineering across HPE’s HPC and AI portfolio, including large-model training platforms and Cray exascale systems. His teams define product strategy, performance architecture, and deployment models that position HPE at the forefront of high-performance and AI computing.
During his nine years at HPE, Chris has led key initiatives across Performance Engineering, AI Cloud, and Professional Services, shaping how HPE delivers optimized, cloud-native, and globally deployed high-performance systems. He previously held technical and leadership roles in the biotech and medical diagnostics sectors. Chris holds an M.B.A. in Entrepreneurship and Finance and a B.S. in Biology from Loyola University Chicago. Arjun Shankar, Division Director, National Center for Computational Science, Oak Ridge National Laboratory Mallikarjun (Arjun) Shankar is the Division Director for the National Center for Computational Science at the Oak Ridge National Laboratory. His research focuses on the interdisciplinary bridge between computer science and large-scale scientific discovery campaigns that rely on scalable computing and data science. He is a joint faculty appointee at the University of Tennessee’s Bredesen Center, a senior member of the IEEE and a senior member of the ACM.

What’s next for IVF
EXECUTIVE SUMMARY Forty-eight years ago this July, Louise Joy Brown became the world’s first person born with the help of in vitro fertilization. Millions more IVF babies have entered the world since then. And that’s partly thanks to advances in technology that have made IVF safer and more effective. But it’s still not perfect. The process can be slow, painful, and expensive—and that’s for the lucky people who are able to access it in the first place. And by at least one measure, IVF success rates have been declining in recent years. Reproduction is complex, and there’s a lot that embryologists and gynecologists still don’t know and can’t control. They don’t know why many healthy-looking embryos don’t “stick” in the uterus, for example. They don’t always have an explanation for why their patients can’t get pregnant. And they can’t always account for vast differences in IVF success rates between individuals and between fertility clinics. Scientists are working on all those questions and more. They’re wrestling with complex ethical questions about how new genetic tools will be used to analyze or even alter embryos. Meanwhile, technologies designed to standardize treatment, eliminate human error, boost success rates, and make IVF more accessible are already beginning to usher in a new era for assisted reproduction—one aided by AI and robots.
1. Helping embryos stick Some of those technologies are being developed at the Carlos Simon Foundation in Valencia, Spain. When I visited in March, researchers gave me a tour of the labs and showed me a device that had been used to keep a human uterus alive outside the body for the first time. While some members of the team dream of building artificial uteruses that might one day be able to carry a fetus to term, they first want to use such devices to learn more about implantation—the moment at which a fertilized egg makes contact with the lining of the uterus, burrows inside, and essentially “hatches,” triggering the start of a pregnancy.
Despite decades of advances in IVF, that process is still poorly understood. Even healthy-looking embryos stick no more than 40% to 60% of the time. In IVF techniques used today, clinics can create early-stage embryos and wait until the uterus is deemed most receptive, but once they insert the embryo into the uterus, it’s on its own. Xavier Santamaria, senior clinical scientist at the Carlos Simon Foundation, and his colleagues are trialing a different approach. They’ve developed a device that, at the press of a button, injects the embryo into the uterine lining. JESS HAMZELOU / MITTR In a demonstration I watched with a prototype, Santamaria picked up his speculum and turned to face the vaginal opening of his “patient,” which in this case was just a model of the real thing—a plastic bottom with labia, a vagina, a uterus, and ovaries, two short stumps representing what would normally be a pair of legs held in stirrups. He hunched over and peered inside. “Embryo,” he called. His colleague Maria Pardo, an embryologist, passed him a thin needle containing a mouse embryo she had recently collected from a petri dish. Santamaria’s device allows for the embryo-containing needle to be connected to a delivery tube. This tube also has a camera, a light, and a sensor that lets the doctor know when the needle reaches the uterine lining. Once it has been fed into the uterus, the gynecologist can see the inside of the organ and direct the tube to the lining. JESS HAMZELOU / MITTR “When everything is ready, you just press the button,” Santamaria said as he activated it using a foot pedal, allowing the embryo to be injected. “There it goes.” The team has just started a trial of the device; so far, fewer than 10 women have undergone the procedure, and none of those have become pregnant. But foundation director Carlos Simon is hopeful, noting that the inventors of IVF had to perform over 160 cycles before Louise Brown was born (between 1969 and 1978, that team performed 457 cycles in 250 people, resulting in only two live births). “The trial is ongoing,” he says. 2. Picking the “best” eggs, sperm, and embryos One long-running challenge of IVF has been selection. Say you manage to collect 10 eggs from one partner and a decent-looking semen sample from the other. How do you choose which cells to use? The same question comes up once the resulting embryos have been cultured in a dish for a few days: Which should you transfer to the uterus?
Traditionally, these judgments have been made by eye. Embryologists literally pick the ones that look the best in terms of their shape or, in the case of sperm, how they move. But scientists have been working on alternatives. And over the last decade or so, many have turned to genetic testing to hint at which embryos have the best chances of creating a healthy baby. The most commonly used test is called PGT-A, which stands for preimplantation genetic testing for aneuploidy. Aneuploidy essentially means having an “incorrect” number of chromosomes, and it is thought that embryos with such characteristics are more likely to be lost through miscarriage or potentially develop into babies with genetic conditions. Once embryologists have created embryos in the lab, they can pinch off a few cells and test them for aneuploidies. The tests are especially beneficial for women over the age of 38, says Alan Penzias, a reproductive endocrinologist at Boston IVF. “You start to see an improvement: more babies and fewer miscarriages,” he says. The tests can shorten the time to pregnancy. This type of genetic testing is possible thanks to multiple advances in technology—not just in genomics, but also in the ability to keep embryos alive in a dish for five to six days and the technique of freezing embryos while the cells undergo testing and thawing them once the results are in. And it has become hugely popular—some clinics do PGT-A tests on all their embryos. But PGT-A won’t give you a perfect readout of a future baby’s genetics, says Sonia Gayete-Lafuente, a reproductive endocrinologist at the Center for Human Reproduction in New York City. And some of the abnormalities might be able to self-correct with time. Gayete-Lafuente and her colleagues have transferred some of those “abnormal” embryos into patients’ uteruses and seen them develop into perfectly healthy children, she says. Other forms of PGT are even more controversial. PGT-P tests are designed to predict an embryo’s chances of developing complex traits that rely on multiple genes, including medical disorders but also physical characteristics like height or cognitive factors like IQ. These tests are new, and they are illegal in some countries, including the UK. But they are gaining ground in the US. Nucleus Genomics—a company that invites customers to “have [their] best baby”—promises to predict traits running the gamut from eye color and intelligence to left-handedness and risk of Alzheimer’s. When I asked IVF practitioners how they might respond if a patient asked for this service, most dodged the question and told me there’s not enough evidence that any of these tests actually work. They also cautioned that selecting for one trait might inadvertently introduce new risks. None seemed especially keen on the idea of using genetic testing for anything other than preventing serious disease. 3. Speeding things up with AI Some seemed more excited about the potential for AI. After all, AI tools are generally good at recognizing patterns. Many researchers have attempted to train tools to spot healthy sperm, eggs, and embryos.
And they’ve had some success. A team at Columbia University Medical Center in New York has developed a device that uses AI to examine semen samples from men who have only tiny numbers of healthy sperm. An embryologist might struggle to find a single healthy sperm in such a sample. But the Sperm Tracking and Recovery (STAR) system can analyze over a million microscope images in an hour. It has already been used to create healthy embryos. The team behind the work announced the first pregnancy resulting from the treatment in November last year. Other teams are using AI tools to advance IVF in more dramatic ways. Around a decade ago, a reproductive endocrinologist named Alejandro Chavez-Badiola began developing an AI tool trained to rank embryos, another to rank eggs, and another to select sperm. He recalls being struck by a realization that these tools were “the brains that have the potential to drive robots in the future,” he says.
4. Using robots to standardize IVF In the early 2020s, Chavez-Badiola and his colleagues decided to combine technologies and develop an automated system for IVF. In theory, a robotic system loaded up with AI tools could undertake most of the steps required in the IVF process: selecting the eggs and sperm, fertilizing eggs to create embryos, culturing those embryos in a dish, and selecting the “best” one for transfer. Such a system could “do everything in a standard way” without ever getting tired, he says. Chavez-Badiola, who is now founder and chief medical officer at Conceivable, started building prototypes by motorizing regular IVF equipment and connecting it to computers. He and his colleagues started testing their system with animal cells before eventually moving on to human ones. “We were able to prove that integrating robots to automate different steps in IVF is doable,” he says. The device is now being used to prepare sperm and eggs and create embryos. At least 19 children have been born following the automated IVF. It is early days, but Chavez-Badiola is hoping that future iterations of the machine could each process thousands of IVF cycles in a year, potentially making the procedure more affordable and accessible. Many in the field are excited about the potential for automated devices like Conceivable’s. “This is all time saved for the embryologists,” says Laura Rienzi, a clinical embryologist and scientific director of the IVIRMA network of fertility centers in Italy. She also hopes it will help standardize IVF treatments. “Automation [will allow for] every patient to be treated in the same way in every single lab in the world,” she says. 5. Controversial edits are on the table There’s a catch, however: All these technologies rely on the availability of at least some healthy sperm, eggs, and embryos at the outset. Embryologists and IVF patients have to work with what they’ve got. And sometimes, what they’ve got won’t result in a healthy baby. That’s why some scientists are proposing a controversial idea: using gene-editing technologies like CRISPR to tinker with the genome of an IVF embryo before it is implanted. The biophysicist He Jiankui infamously took this approach to create embryos that resulted in the births of three children in the late 2010s. He was widely condemned by the scientific community and ultimately spent three years in a Chinese prison.
His former romantic partner Cathy Tie, who now leads startup Origin Genomics, is pursuing the technology as a potential way to prevent serious disease in children. At a recent event held at the Hastings Center for Bioethics, Tie made the case for using embryo editing to prevent diseases like cystic fibrosis, Huntington’s, and sickle-cell. It won’t be straightforward from a technical, legal, or ethical perspective. Diseases that are known to be caused by single-gene mutations are good first candidates, but as the Center for Human Reproduction’s Gayete-Lafuente points out, most diseases are much more complicated than that. “I wish we could understand the genetic basis of every disease to be able to prevent it,” she says. So far, we can’t. Besides, most diseases can be influenced by our diets, behaviors, and environments as well as our genes. As things stand, no one knows if editing a human embryo to eliminate the risk of one disease might increase a future child’s risk of some other disorder. And some scientists worry that such edits might be a slippery slope to genetic enhancement or eugenics. Rienzi hopes that the technology might be developed in a safe way with regulatory oversight, and only for a specific list of diseases. “It has to be within a legal context,” she says. “But to me, it’s a dream.” In the meantime, the field looks set to keep transforming with the development of new technologies that are already creating healthy babies. Watch this space.

Supply constraints, optical advances dominate Arista’s Q1
“While the industry has been talking a lot about co-packaged optics, these are still science experiments, and they’re very proprietary with individual vendors doing their own thing. We’ll embrace open CPO a few years from now, but we think XPO has a 10-year run, especially at 1.6T and 3.2T where you need liquid cooling and you need that kind of capacity. So, all the scale-up racks we’re talking about wouldn’t be possible without XPO or CPC or any one of those technologies,” Ullal said. “Just as the last decade was greatly influenced by OSFP, the next decade will be greatly influenced by XPO,” Ullal said. “And remember, 99% of the optical market today that we connect to is all pluggable optics. So this is a very crucial invention and innovation, not just for Arista, but the industry at large.” Enterprise AI: Calm before the storm? When it comes to AI for enterprise network customers, Arista’s Ullal says it’s just getting started. The company is seeing a shift from AI training toward more AI inference, “which means you don’t always need the GPU,” Ullal said. “You’re going to have high-end CPUs, and you’re going to have a smaller set of parameters and tokens to manage, and you’re going to have specific agentic AI use cases and applications. We’re seeing very, very early trials and stages. Nothing super big yet.” Some customers are deploying clusters that are “more inference-based, more agentic AI, edge, inference-based as well,” Ullas said. “I think we’ll see more of that. This is the calm before the storm, if you will. As AI gets more distributed, I think it doesn’t need GPUs alone. It’s going to need more high-performance compute… I think it’s gonna take a couple of years to fully happen.”

Lumen advances cloud networking vision with $475M Alkira buy
Lumen puts its total addressable market at approximately $70 billion once Alkira’s international and cloud-to-cloud coverage is included. “Alkira is a bull’s eye in terms of strategic alignment and value creation,” Johnson said. “For Lumen, we expect it to dramatically accelerate our road map execution from years to months.” How the architecture works Alkira operates as a cloud-native, carrier-agnostic control plane. Rather than relying on physical hardware at each interconnection point, it uses a virtual port model that lets enterprises design, deploy and manage network connectivity across clouds, data centers and on-premises environments through a single interface. Alkira is distinct from Lumen’s existing Project Berkeley, which introduces fabric ports for building-to-cloud on-ramp connectivity. “Fabric ports is about enabling building on-prem to be able to connect to the cloud and to be able to grow those services in a cloud economic way,” Johnson said. “The Alkira platform really focuses on the East-West interconnect. So that’s data center-to-data center, cloud-to-cloud, so they operate with more of a virtual port kind of a model, and it’s better together.” Lumen’s Multi-Cloud Gateway bridges the two domains, enabling customers to connect any cloud and any data center over Lumen’s private network. After close, Multi-Cloud Gateway and Alkira together are intended to give customers a single control plane for routing, policy and security across both north-south and east-west connectivity.

NNPC advances rehab, expansion plans for idled refineries
Nigeria National Petroleum Corp. Ltd. (NNPC) has entered a memorandum of understanding (MOU) with China-based Sanjiang Chemical Co. Ltd. and Xinganchen (Fuzhou) Industrial Park Operation and Management Co. Ltd. for collaboration via a potential technical equity partnership to support ongoing rehabilitation and expansion plans at two of its currently idled in-country refining complexes. Announced in early May, the MOU’s proposed framework covers unspecified remaining rehabilitation works at subsidiary Warri Refining & Petrochemical Co. Ltd.’s (WRPC) 125,000-b/sd refinery in Nigeria’s Delta State and Port Harcourt Refining Co. Ltd.’s (PHRC) 60,000-b/sd hydroskimming refinery at Alesa-Eleme near Port Harcourt in Rivers State, NNPC said. Alongside operating and maintenance activities to help the sites achieve best-in-class, sustainable performance, the MOU also outlines proposed expansions and upgrades at both refineries to enable production of cleaner, higher-valued products, according to the company. While NNPC did not clarify the nature of expansion and upgrading plans for either of the refining sections of the sites, the operator said the potential collaboration with Sanjiang Chemical and and Xinganchen (Fuzhou) Industrial Park also would weigh options for expanding the two complex’s petrochemical capabilities, as well as future development of co-located, gas-based industrial hubs at the two locations. NNPC said formal signing of the MOU follows more than 6 months of technical and management discussions with the two Chinese firms to develop a roadmap for restoring sustained, high-performance manufacturing operations at both sites. The MOU comes as part of NNPC’s broader mission to identify potential privately held technical equity partners to help support rehabilitation and expansion of its existing but nonoperational refining infrastructure, which ideally would include a willingness to evaluate opportunities for adding co-located petrochemical production and gas-based industries at the sites, the operator said. The agreement with Sanjiang Chemical and and Xinganchen (Fuzhou) Industrial Park follows NNPC’s announcement earlier

OTC speakers say Venezuela reopening hinges on stability, legal clarity
The conversation comes as the Trump administration continues easing sanctions and encouraging American operators to re-engage with Venezuela’s oil and gas sector. Signs are growing that major international energy companies are reassessing opportunities in the country. ExxonMobil and ConocoPhillips have recently dispatched technical teams to evaluate oilfield infrastructure and upstream prospects, while Gulf Coast refiners have already increased imports of Venezuelan heavy crude. Panelists said the central question facing US energy companies is no longer whether Venezuela will reopen, but whether the conditions, pace, and overall risk profile of that reopening are sufficient to support large-scale, long-term capital investment. Speakers noted that Venezuela’s appeal extends far beyond short-term political change. The country holds one of the world’s largest and most diverse hydrocarbon resource bases, including extra-heavy crude in the Orinoco Belt, conventional light and medium oil, and significant offshore natural gas resources. The opportunity lies not only in the size of the resource base, but also in the long-term development potential, the panelists said. However, years of underinvestment, deteriorating infrastructure, and labor losses mean rebuilding the sector will require significant technical expertise and sustained capital commitments. Oilfield service companies are expected to play an important role if activity accelerates, particularly in offshore gas, heavy oil upgrading, drilling services, and infrastructure rehabilitation. Recent reports indicate service providers have already begun reactivating rigs and equipment stored in Venezuela in anticipation of renewed activity. Speakers emphasized that investors are seeking stable policies and durable legal frameworks before committing capital at scale. Trust in Venezuela’s legal and regulatory system remains weak following years of expropriations and contract disputes. Companies must evaluate not only Venezuela’s domestic political outlook, but also the broader geopolitical dynamics involving the US and China, Borrego noted. China’s long-standing investments and influence in Venezuela’s energy sector were referenced as an important

HPE bolsters autonomous network operations for Mist, Aruba Central
Outside of the wireless realm, HPE has added the ability to autonomously fix VLAN configuration errors in the access layer to prevent blackholing of client traffic and detect/remediate unauthorized DHCP servers. The idea is to mitigate potential external security risks and prevent end user connectivity disruptions, according to a blog post penned by Selena Mosley, HPE Marvis product marketing manager. “A rogue DHCP server—often introduced unintentionally through a BYOD device—can misassign IP addresses and take down entire areas. Marvis detects the anomaly, traces it to the exact switch port, and can automatically contain it, reducing blast radius and restoring service quickly,” Mosley wrote. “Or consider missing VLANs, a common cause of connected but not working scenarios during day‑0 or day‑2 changes. Marvis correlates client telemetry, configuration state, and Marvis Minis validations to identify the mismatch and either remediate automatically or guide the operator with a single action. In each case, the outcome is the same: fewer escalations, faster resolution, and consistent application experience,” Mosley wrote.
Stay Ahead with the Paperboy Newsletter
Your weekly dose of insights into AI, Bitcoin mining, Datacenters and Energy indusrty news. Spend 3-5 minutes and catch-up on 1 week of news.